Most practitioners ordering a CMP already have mitochondrial uncoupling lab markers in front of them. They’re just not reading them that way. AST, ALT, lactate, ammonia – these values routinely appear on standard panels, and in the right clinical context, they tell a coherent story about mitochondrial bioenergetic failure. Dr. Datis Kharrazian’s clinical training at the Kharrazian Institute teaches practitioners to extract that story from labs they’re already running, without ordering a single specialized test.
Mitochondrial dysfunction is not limited to rare genetic disorders. Research across neurology, immunology, and metabolic medicine demonstrates that acquired mitochondrial dysfunction is a significant driver of chronic fatigue syndromes, post-viral sequelae including post-COVID-19 conditions, autism spectrum disorder, and a wide range of inflammatory and degenerative presentations. The clinical challenge is that most practitioners have no systematic thought process for assessing it without expensive or inaccessible specialty testing.
Standard labs can fill that gap – if you know what you’re looking for.
Primary vs. Acquired Mitochondrial Dysfunction: The Clinical Distinction That Matters
Primary mitochondrial dysfunction involves genetic mutations affecting the electron transport chain or mitochondrial DNA. These cases are relatively rare and typically diagnosed in pediatric or specialized neurology settings. Acquired mitochondrial dysfunction is the far more common clinical presentation, and it’s what most practitioners encounter without recognizing it.
Acquired dysfunction develops when environmental inputs impair mitochondrial function in otherwise structurally intact mitochondria. Diet quality, sleep deprivation, chronic psychological stress, heavy metal exposure, pharmaceutical agents (particularly statins, metformin, and certain antibiotics), and viral infections have all been shown to impair mitochondrial respiration. Post-SARS-CoV-2 presentations are among the most well-documented current examples – research in post-COVID-19 literature consistently implicates mitochondrial bioenergetic failure in the fatigue and cognitive symptom clusters.
This distinction matters clinically because acquired dysfunction is, in principle, addressable. Identifying it early gives you a therapeutic target. Identifying it from standard labs gives you a cost-effective entry point into that process.
Lactate and Pyruvate: The Front-Line Bioenergetic Signal
When aerobic respiration is functioning normally, pyruvate enters the mitochondria via pyruvate dehydrogenase and feeds into the Krebs cycle. When mitochondrial function is impaired, pyruvate accumulates in the cytoplasm and is converted to lactate. Elevated lactate is the biochemical signature of a cell that has lost aerobic efficiency and is running on anaerobic metabolism.
Elevated lactate alone can indicate many things – acute illness, tissue hypoxia, liver dysfunction. The lactate-to-pyruvate ratio is more specific. A ratio above 20:1 is consistent with impaired electron transport chain function, while a ratio below 20:1 with elevated lactate and pyruvate together suggests pyruvate dehydrogenase deficiency or another upstream block. Clinically, this distinction narrows the differential considerably.
Specimen handling is critical here. Lactate levels are highly sensitive to collection conditions. Blood collected with a tourniquet, transported without immediate chilling, or processed with delay will produce artificially elevated results. Patients should be fasting, resting, and not have exercised within 24 hours. The blood must be collected without a tourniquet, placed immediately on ice, and processed within 15 minutes. Results obtained outside these conditions should not be interpreted as meaningful negatives or positives.
Dr. Kharrazian’s clinical teaching places significant emphasis on collection protocol – not because it’s procedurally interesting, but because a falsely normal lactate in a patient with genuine mitochondrial dysfunction ends the clinical inquiry prematurely.
Carnitine: The Fatty Acid Transport Marker Most Labs Ignore
Mitochondria cannot oxidize long-chain fatty acids without carnitine. The carnitine shuttle – specifically the CPT1 and CPT2 enzyme system – is the gate through which fatty acids enter the inner mitochondrial membrane for beta-oxidation. When this system is impaired, or when carnitine itself is depleted, fatty acid oxidation stalls and cells must rely disproportionately on glucose and anaerobic pathways.
Total carnitine and free carnitine levels are measurable on standard specialty labs, though they’re not typically included in routine metabolic panels. Low free carnitine suggests either inadequate synthesis, inadequate dietary intake, or accelerated loss through renal wasting. Low total carnitine with a disproportionate reduction in free carnitine (and a corresponding rise in the acylcarnitine-to-free carnitine ratio) points toward impaired beta-oxidation – the mitochondria are accumulating acylcarnitine intermediates because they cannot complete the oxidative process.
Research in pediatric mitochondrial disease has used acylcarnitine profiles for decades as a primary screening tool. In adults with chronic fatigue presentations, carnitine status is less consistently assessed, which represents a clinical gap. A patient with low free carnitine, elevated lactate, and nonspecific fatigue is presenting a coherent mitochondrial picture that most standard workups will miss entirely.
Ammonia, the Urea Cycle, and Mitochondrial Stress
Ammonia elevation in the context of mitochondrial dysfunction is mechanistically straightforward. The urea cycle, which is responsible for converting toxic ammonia to urea for renal excretion, is partially mitochondria-dependent. Carbamoyl phosphate synthetase 1 (CPS1), the first enzyme in the urea cycle, operates inside the mitochondrial matrix. When mitochondrial function is compromised, CPS1 activity declines, urea cycle efficiency drops, and ammonia accumulates.
Simultaneously, impaired aerobic metabolism increases reliance on amino acid catabolism as a fuel source, which generates additional ammonia as a byproduct. The result is a dual insult: ammonia production increases while the mechanism to clear it is impaired.
Elevated fasting ammonia in a patient without liver disease or overt hepatic encephalopathy warrants scrutiny. In the context of fatigue, cognitive symptoms, and the other markers discussed here, it’s a meaningful signal. Reference ranges on standard panels are designed to catch frank hyperammonemia. Levels at the upper range of normal – particularly in a patient with a consistent clinical picture – deserve clinical attention rather than dismissal.
Tissue Damage Markers as Indirect Mitochondrial Signals
High-energy tissues – cardiac muscle, skeletal muscle, liver, brain – have the highest mitochondrial density in the body. They are also the first to sustain damage when mitochondrial ATP production fails. CK, AST, and ALT are standard markers of cellular integrity in these tissues, and their elevation in the absence of an obvious structural cause should prompt consideration of bioenergetic failure.
Creatine kinase is particularly useful. Elevated CK in a patient with fatigue and exercise intolerance, without identifiable muscle injury or inflammatory myopathy, suggests that muscle cells are not maintaining ATP-dependent membrane integrity. The mitochondria are not generating sufficient energy to keep up with cellular maintenance demands.
AST elevation that exceeds ALT elevation – the reversed ratio – can suggest muscle rather than hepatocellular origin, since AST is present in both muscle and liver while ALT is more liver-specific. This pattern, alongside elevated CK, strengthens the case for a systemic mitochondrial process rather than isolated hepatic pathology.
None of these markers are definitive in isolation. The clinical value of this approach lies in pattern recognition. A patient presenting with fatigue, elevated lactate, low carnitine, mildly elevated ammonia, and elevated CK is not presenting five unrelated lab abnormalities. They are presenting one coherent picture of mitochondrial bioenergetic failure, and that picture warrants a clinical response.
Pulling the Markers Together: A Practical Thought Process
Dr. Kharrazian’s coursework at the Kharrazian Institute provides practitioners with a systematic clinical strategy for interpreting these markers in sequence rather than in isolation. The thought process begins with the most accessible signals – CMP and CBC – and builds toward more targeted markers as the picture develops.
Start with AST, ALT, and the AST-to-ALT ratio. Add CK if muscle involvement is suspected or if the patient reports exercise intolerance or post-exertional worsening. Order fasting lactate under proper collection conditions. Assess ammonia if the patient has cognitive symptoms, particularly brain fog, that are disproportionate to other findings. Add carnitine fractionation when fatigue is a primary complaint and the rest of the picture is consistent.
This sequenced approach does not require expensive specialty panels at entry. It requires knowing which standard markers carry mitochondrial signal and how to read them together. The correlation between these biochemical markers and diagnosed mitochondrial disorders is still an area of ongoing research, and these labs are not diagnostic in isolation. Their clinical utility is in directing further evaluation, supporting clinical reasoning, and identifying patients who may benefit from targeted mitochondrial support protocols before more invasive testing becomes necessary.
Practitioners working with complex chronic fatigue cases, post-viral patients, or individuals on long-term pharmaceutical regimens that impair mitochondrial function will find this approach immediately applicable. The labs are already there. The question is whether the interpretation is.
Key Takeaways
- Acquired mitochondrial dysfunction is far more common than primary genetic mitochondrial disease and is identifiable through standard lab markers when interpreted systematically.
- The lactate-to-pyruvate ratio provides more specific signal than lactate alone; specimen collection protocol directly determines result validity.
- Low free carnitine with a disproportionate rise in acylcarnitine intermediates points toward impaired beta-oxidation and fatty acid energy failure.
- Elevated fasting ammonia in the absence of liver disease may reflect urea cycle impairment secondary to mitochondrial dysfunction, particularly in patients with cognitive symptoms.
- Pattern recognition across CK, AST, ALT, lactate, ammonia, and carnitine produces a clinically actionable picture; no single marker is sufficient in isolation.
Frequently Asked Questions
Clinically useful markers include elevated lactate and pyruvate (particularly the ratio), low free carnitine, elevated fasting ammonia, and elevated CK, AST, or ALT without an identified structural cause. These markers are most informative when interpreted as a pattern across a consistent clinical presentation.
Primary mitochondrial disease involves genetic defects affecting mitochondrial structure or the electron transport chain. Acquired dysfunction results from environmental inputs – medications, infections, sleep deprivation, toxin exposure – that impair function in structurally intact mitochondria. Acquired dysfunction is significantly more common and more clinically accessible to address.
Lactate is produced continuously by red blood cells and muscle. Tourniquet use, delayed processing, and warm transport accelerate ex vivo lactate production, artificially elevating results. Valid lactate measurement requires no tourniquet, immediate ice, and processing within 15 minutes of collection. Deviations from this protocol invalidate the result.
Standard labs do not replace muscle biopsy, respiratory chain enzyme assays, or mitochondrial DNA sequencing when those are clinically indicated. Their value is as an accessible entry point – identifying patients whose pattern warrants further evaluation and supporting clinical reasoning in complex chronic cases where specialty testing may not yet be justified or accessible.
Patients with chronic fatigue, post-viral syndromes (including post-COVID-19), exercise intolerance, unexplained cognitive symptoms, or long-term use of mitochondrial-impairing pharmaceuticals such as statins or certain antibiotics represent the highest-yield populations for systematic mitochondrial marker assessment.
About the Author
Dr. Datis Kharrazian, PhD, DHSc, DC, MS, MMSc, FACN, is a Harvard Medical School research fellow and researcher at Massachusetts General Hospital’s Department of Neurology specializing in autoimmunity and neuroimmunology. He serves as Associate Clinical Professor at Loma Linda University School of Medicine and is the author of Why Do I Still Have Thyroid Symptoms When My Lab Tests Are Normal and Why Isn’t My Brain Working. He holds fellowships with the American College of Nutrition and the Royal Society of Medicine (UK), is a Diplomate of the Board of Nutrition Specialists, and is a member of the American Association of Immunologists. The Kharrazian Institute provides clinical education and training to more than 5,000 physicians and healthcare providers worldwide.
Continue Your Training
The Kharrazian Institute offers advanced clinical training in mitochondrial dysfunction assessment and related chronic disease applications. Practitioners seeking a systematic, evidence-based thought process for applying these markers in complex cases can find the full coursework at kharrazianinstitute.com.
